Graham Capital Management, L.P. Viridian Therapeutics, Inc.\De Transaction History
Graham Capital Management, L.P.
- $3.11 Billion
- Q2 2024
A detailed history of Graham Capital Management, L.P. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Graham Capital Management, L.P. holds 22,444 shares of VRDN stock, worth $472,670. This represents 0.01% of its overall portfolio holdings.
Number of Shares
22,444Holding current value
$472,670% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding VRDN
# of Institutions
149Shares Held
60.7MCall Options Held
134KPut Options Held
238K-
Black Rock Inc. New York, NY4.77MShares$101 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.92MShares$82.6 Million1.68% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$81.8 Million5.54% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.35MShares$70.5 Million0.0% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx3.31MShares$69.7 Million0.85% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $840M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...